Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn’t Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.
Key Points Obesity drugs like Mounjaro and Zepbound could help the drugmaker power ahead for years. Its Alzheimer’s drug Kisunla and broad pipeline add another layer of long-term potential. My take: Lilly looks like a compelling long-term company, but its premium valuation merits consideration. 10 stocks we like better than Eli Lilly › In the…